Therefore, TEM8 antagonists have the potential to deliver a double blow to solid tumors, disabling their exploitation of stromal-derived nutrients while preserving the restriction-mediated functions of intact collagen I. In combination with other anti-cancer agents, TEM8 antagonists provide a promising approach for improved cancer therapy against multiple solid tumor types. Here, ANTXR1 is linked to cancer.